MA26958A1 - Derives de 2-phenylaminoimidazoline phenyl cetone substituee en tant qu'antagonistes ip - Google Patents

Derives de 2-phenylaminoimidazoline phenyl cetone substituee en tant qu'antagonistes ip

Info

Publication number: MA26958A1
Authority: MA; Morocco
Prior art keywords: phenylaminoimidazoline; antagonists; phenyl ketone; ketone substituted; derivatives phenyl
Prior art date: 2000-11-14

Application number

MA27154A

Other languages

English (en)

Inventor

Alam Jahangir

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-14

Filing date

2003-05-12

Publication date

2004-12-20

2003-05-12 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2004-12-20 Publication of MA26958A1 publication Critical patent/MA26958A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

MA27154A 2000-11-14 2003-05-12 Derives de 2-phenylaminoimidazoline phenyl cetone substituee en tant qu'antagonistes ip MA26958A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US24888800P	2000-11-14	2000-11-14

Publications (1)

Publication Number	Publication Date
MA26958A1 true MA26958A1 (fr)	2004-12-20

Family

ID=22941114

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA27154A MA26958A1 (fr)	2000-11-14	2003-05-12	Derives de 2-phenylaminoimidazoline phenyl cetone substituee en tant qu'antagonistes ip

Country Status (29)

Country	Link
EP (1)	EP1339694B1 (fr)
JP (1)	JP4108474B2 (fr)
KR (1)	KR100562605B1 (fr)
CN (1)	CN1267423C (fr)
AR (1)	AR035502A1 (fr)
AT (1)	ATE305002T1 (fr)
AU (1)	AU2180802A (fr)
BG (1)	BG107814A (fr)
BR (1)	BR0115291A (fr)
CA (1)	CA2427900A1 (fr)
CZ (1)	CZ20031596A3 (fr)
DE (1)	DE60113563T2 (fr)
EC (1)	ECSP034602A (fr)
ES (1)	ES2248413T3 (fr)
HU (1)	HUP0303156A3 (fr)
IL (1)	IL155436A0 (fr)
MA (1)	MA26958A1 (fr)
MX (1)	MXPA03004073A (fr)
NO (1)	NO20032142L (fr)
NZ (1)	NZ525330A (fr)
PA (1)	PA8532201A1 (fr)
PE (1)	PE20020602A1 (fr)
PL (1)	PL362549A1 (fr)
RU (1)	RU2284995C2 (fr)
SK (1)	SK7222003A3 (fr)
UY (1)	UY27023A1 (fr)
WO (1)	WO2002040453A1 (fr)
YU (1)	YU37203A (fr)
ZA (1)	ZA200303413B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004071508A1 (fr) *	2003-02-14	2004-08-26	Medical Research Council	Antagonistes du recepteur ip utilises dans le traitement des pathologies de l'uterus
MXPA05011476A (es) *	2003-05-01	2005-12-12	Hoffmann La Roche	Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2.
EP1635834A4 (fr) *	2003-06-25	2009-12-02	Smithkline Beecham Corp	Nouveaux composes
BRPI0411867A (pt) *	2003-07-09	2006-08-08	Hoffmann La Roche	tiofenilaminoimidazolinas
WO2007090720A2 (fr) *	2006-01-27	2007-08-16	F. Hoffmann-La Roche Ag	Utilisation de 2-imidazoles pour le traitement de troubles du système nerveux central
AU2007312390B2 (en)	2006-10-19	2013-03-28	F. Hoffmann-La Roche Ag	Aminomethyl-4-imidazoles
CA2668454A1 (fr)	2006-11-02	2008-05-08	F. Hoffmann-La Roche Ag	2-imidazoles substitues en tant que modulateurs des recepteurs associes aux amines de trace
EP2084152A2 (fr)	2006-11-16	2009-08-05	F. Hoffmann-Roche AG	4-imidazoles substitués
EP2101762B1 (fr)	2006-12-13	2011-05-18	F. Hoffmann-La Roche AG	Nouveaux 2-imidazoles comme ligands pour récepteurs associés à une amine de trace (taar)
US20080146523A1 (en)	2006-12-18	2008-06-19	Guido Galley	Imidazole derivatives
JP5248528B2 (ja)	2007-02-02	2013-07-31	エフ．ホフマン−ラロシュアーゲー	Ｃｎｓ疾患用のｔａａｒ１リガンドとしての新規２−アミノオキサゾリン
CN101616902B (zh)	2007-02-15	2013-03-27	弗·哈夫曼-拉罗切有限公司	作为taar1配体的2-氨基*唑啉类化合物
CA2691082A1 (fr)	2007-07-02	2009-01-08	F. Hoffmann-La Roche Ag	2-imidazolines
CA2691704A1 (fr)	2007-07-03	2009-01-08	F. Hoffmann-La Roche Ag	4-imidazolines et leur utilisation comme antidepresseurs
WO2009016048A1 (fr)	2007-07-27	2009-02-05	F. Hoffmann-La Roche Ag	2-azétidineméthaneamines et 2-pyrrolidineméthaneamines comme ligands de taar
WO2009019149A1 (fr)	2007-08-03	2009-02-12	F. Hoffmann-La Roche Ag	Dérivés de pyridinecarboxamide et de benzamide servant de ligands de taar1
US8242153B2 (en)	2008-07-24	2012-08-14	Hoffmann-La Roche Inc.	4,5-dihydro-oxazol-2YL derivatives
US8354441B2 (en)	2009-11-11	2013-01-15	Hoffmann-La Roche Inc.	Oxazoline derivatives
EP2513064B1 (fr)	2009-12-17	2018-07-04	Katholieke Universiteit Leuven, K.U. Leuven R&D	Composé, compositions et procédés de lutte contre les biofilms
US9452980B2 (en)	2009-12-22	2016-09-27	Hoffmann-La Roche Inc.	Substituted benzamides
WO2014143592A1 (fr)	2013-03-12	2014-09-18	Allergan, Inc.	Inhibition de la néovascularisation par inhibition des récepteurs de prostanoïde ip
WO2014143591A1 (fr)	2013-03-12	2014-09-18	Allergan, Inc.	Inhibition de la néovascularisation par inhibition simultanée de prostanoïde ip et des récepteurs ep4
US9827225B2 (en) *	2016-01-25	2017-11-28	Jenivision Inc.	Use of prostacyclin antagonists for treating ocular surface nociception
HUE050986T2 (hu)	2016-03-17	2021-01-28	Hoffmann La Roche	5-etil-4-metil-pirazol-3-karboxamid származék, amely TAAR-agonista aktivitású

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4889868A (en) *	1984-12-20	1989-12-26	Rorer Pharmaceutical Corporation	Bis-imidazolinoamino derivatives as antiallergy compounds
GB9506188D0 (en) *	1995-03-27	1995-05-17	Fujisawa Pharmaceutical Co	Amidine derivatives
NZ331480A (en) *	1997-09-04	2000-02-28	F	2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions

2001
- 2001-11-05 KR KR1020037006504A patent/KR100562605B1/ko not_active IP Right Cessation
- 2001-11-05 IL IL15543601A patent/IL155436A0/xx unknown
- 2001-11-05 ES ES01996531T patent/ES2248413T3/es not_active Expired - Lifetime
- 2001-11-05 HU HU0303156A patent/HUP0303156A3/hu unknown
- 2001-11-05 MX MXPA03004073A patent/MXPA03004073A/es active IP Right Grant
- 2001-11-05 BR BR0115291-2A patent/BR0115291A/pt not_active IP Right Cessation
- 2001-11-05 SK SK722-2003A patent/SK7222003A3/sk unknown
- 2001-11-05 AU AU2180802A patent/AU2180802A/xx not_active Withdrawn
- 2001-11-05 NZ NZ525330A patent/NZ525330A/en unknown
- 2001-11-05 CA CA002427900A patent/CA2427900A1/fr not_active Abandoned
- 2001-11-05 CN CNB018187471A patent/CN1267423C/zh not_active Expired - Fee Related
- 2001-11-05 CZ CZ20031596A patent/CZ20031596A3/cs unknown
- 2001-11-05 EP EP01996531A patent/EP1339694B1/fr not_active Expired - Lifetime
- 2001-11-05 PL PL01362549A patent/PL362549A1/xx unknown
- 2001-11-05 AT AT01996531T patent/ATE305002T1/de not_active IP Right Cessation
- 2001-11-05 DE DE60113563T patent/DE60113563T2/de not_active Expired - Fee Related
- 2001-11-05 WO PCT/EP2001/012776 patent/WO2002040453A1/fr active IP Right Grant
- 2001-11-05 JP JP2002542781A patent/JP4108474B2/ja not_active Expired - Fee Related
- 2001-11-05 RU RU2003115426/04A patent/RU2284995C2/ru not_active IP Right Cessation
- 2001-11-05 YU YU37203A patent/YU37203A/sh unknown
- 2001-11-09 PE PE2001001118A patent/PE20020602A1/es not_active Application Discontinuation
- 2001-11-13 PA PA20018532201A patent/PA8532201A1/es unknown
- 2001-11-13 AR ARP010105280A patent/AR035502A1/es not_active Application Discontinuation
- 2001-11-13 UY UY27023A patent/UY27023A1/es not_active Application Discontinuation
2003
- 2003-05-02 ZA ZA200303413A patent/ZA200303413B/en unknown
- 2003-05-12 MA MA27154A patent/MA26958A1/fr unknown
- 2003-05-13 NO NO20032142A patent/NO20032142L/no not_active Application Discontinuation
- 2003-05-13 EC EC2003004602A patent/ECSP034602A/es unknown
- 2003-05-14 BG BG107814A patent/BG107814A/bg unknown

Also Published As

Publication number	Publication date
BR0115291A (pt)	2003-08-19
RU2284995C2 (ru)	2006-10-10
NZ525330A (en)	2004-10-29
JP2004513940A (ja)	2004-05-13
CZ20031596A3 (cs)	2004-01-14
DE60113563T2 (de)	2006-07-13
KR100562605B1 (ko)	2006-03-17
JP4108474B2 (ja)	2008-06-25
CN1474813A (zh)	2004-02-11
EP1339694A1 (fr)	2003-09-03
SK7222003A3 (en)	2004-05-04
HUP0303156A3 (en)	2004-03-29
PA8532201A1 (es)	2002-08-26
YU37203A (sh)	2006-05-25
ZA200303413B (en)	2004-08-02
ECSP034602A (es)	2003-06-25
PE20020602A1 (es)	2002-07-08
CN1267423C (zh)	2006-08-02
EP1339694B1 (fr)	2005-09-21
AU2180802A (en)	2002-05-27
PL362549A1 (en)	2004-11-02
NO20032142D0 (no)	2003-05-13
WO2002040453A1 (fr)	2002-05-23
MXPA03004073A (es)	2003-09-04
UY27023A1 (es)	2002-06-20
AR035502A1 (es)	2004-06-02
IL155436A0 (en)	2003-11-23
CA2427900A1 (fr)	2002-05-23
BG107814A (bg)	2004-02-27
HUP0303156A2 (hu)	2004-01-28
NO20032142L (no)	2003-05-13
ATE305002T1 (de)	2005-10-15
DE60113563D1 (de)	2006-02-02
KR20030065512A (ko)	2003-08-06
ES2248413T3 (es)	2006-03-16

Publication	Publication Date	Title
MA26958A1 (fr)	2004-12-20	Derives de 2-phenylaminoimidazoline phenyl cetone substituee en tant qu'antagonistes ip
FR20C1039I2 (fr)	2021-08-13	Derives de l'uk-2a
FR17C0008I1 (fr)	2018-12-07	Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2
MA27679A1 (fr)	2006-01-02	Derives d'acides carboxyliques en tant qu'antagonistes ip
MA26972A1 (fr)	2004-12-20	Derives du tetralone en tant qu'agents anti-tumeur
DE60218340D1 (de)	2007-04-05	5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
FR15C0086I2 (fr)	2016-06-03	Derives d'hydroxamate en tant qu'inhibiteurs de desacetylase
MA27083A1 (fr)	2004-12-20	Derives de nicotine ou d'isonicotine benzothiazole
MA27012A1 (fr)	2004-12-20	Derives de dihydro-benzo [b] [1,4] diazepin-2-one en tant qu'antagonistes ii de mglur2
MA26932A1 (fr)	2004-12-20	Derives d'imidazole.
MA27680A1 (fr)	2006-01-02	Derives de 4-phenyl-pyridine en tant qu'antagonistes du recepteur de la neurokinine-1
MA26816A1 (fr)	2004-12-20	Derives d'amino-triazolopyridine
MA27046A1 (fr)	2004-12-20	Nouveaux derives d'oxazolidinones en tant qu'agents antibacteriens.
ATE287883T1 (de)	2005-02-15	Dihydro-benzo(b)(1,4)diazepin-2-on-derivate als mglur2 antagonisten
MA26933A1 (fr)	2004-12-20	Derives de 4-phenyl-pyridine en tant qu'antagonistes de recepteur de la neurokinine 1.
FR2813756B1 (fr)	2003-03-07	Dilueur pour la conservation de spermatozoides de porcins
DE50107988D1 (de)	2005-12-15	Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
ATE334114T1 (de)	2006-08-15	Substituierte c-cyclohexylmethylamin-derivate
ATE309994T1 (de)	2005-12-15	Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
PT1345609E (pt)	2005-08-31	Derivados de tetra-hidro-(benzo ou tieno)-azepina-pirazina como antagonistas de mglur 1
PT1322592E (pt)	2004-12-31	Derivados substituidos de 1-aminobutan-3-ol
MA26941A1 (fr)	2004-12-20	Nouveaux derives d'aminocyclohexane
DE60210058D1 (de)	2006-05-11	Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten
DE60214408D1 (de)	2006-10-12	5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN
NO20042980L (no)	2004-07-14	3,4-dihydro-1H-isokinolin-2-yl-derivater